Changes in serum cholesterol levels determine future risk of cardiovascular events in patients with acute coronary syndrome in the Japanese Coronary Artery Disease (JCAD) Study.

[1]  J. Obata,et al.  A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. , 2012, Journal of cardiology.

[2]  T. Murohara,et al.  Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. , 2012, Journal of cardiology.

[3]  H. Daida,et al.  Intensively lowering both low-density lipoprotein cholesterol and blood pressure does not reduce cardiovascular risk in Japanese coronary artery disease patients. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[4]  R. Collins,et al.  Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. , 2010, Lancet.

[5]  T. Sakamoto,et al.  "Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? (Con). , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[6]  F. Sellke,et al.  Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. , 2010, Atherosclerosis.

[7]  V. Manolopoulos,et al.  Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia , 2010, Heart and Vessels.

[8]  N. Kaneko,et al.  Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[9]  M. Fujita,et al.  Elevated serum C-reactive protein levels predict cardiovascular events in the Japanese coronary artery disease (JCAD) study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[10]  Adrian Hernandez,et al.  Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. , 2009, American heart journal.

[11]  G. Ginsburg,et al.  Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response , 2008, Circulation. Cardiovascular genetics.

[12]  R. Nagai,et al.  Demographics and changes in medical/interventional treatment of coronary artery disease patients over a 3.5-year period in Japan: the Japanese Coronary Artery Disease Study: trend examination. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[13]  D. Rader,et al.  The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. , 2008, Journal of the American College of Cardiology.

[14]  Deborah A Nickerson,et al.  Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment , 2008, Circulation.

[15]  R. Nagai,et al.  Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[16]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[17]  T. Strandberg,et al.  Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. , 2006, Journal of the American College of Cardiology.

[18]  Leiv Ose,et al.  Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[20]  Feng Lin,et al.  Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. , 2006, The American journal of cardiology.

[21]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[22]  K. Shimada,et al.  Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study , 2004, Circulation.

[23]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[24]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[25]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[26]  H. Gylling,et al.  Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. , 2003, The Journal of laboratory and clinical medicine.

[27]  H. Ueshima,et al.  What cause of mortality can we predict by cholesterol screening in the Japanese general population? , 2003, Journal of internal medicine.

[28]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[29]  Y. Matsuzawa,et al.  Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[30]  Y. Matsuzawa,et al.  Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[31]  Toru Suzuki,et al.  Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. , 2002, Clinical biochemistry.

[32]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[33]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[34]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[35]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[36]  D Kromhout,et al.  Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. , 1995, JAMA.

[37]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: Effect of Patient Characteristics on Lovastatin‐Induced Changes in Plasma Concentrations of Lipids and Lipoproteins , 1992, Circulation.

[38]  J P Matts,et al.  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.